Could an arthritis drug boost melanoma treatment?

NCT ID NCT05428007

First seen Jan 11, 2026 · Last updated May 15, 2026 · Updated 21 times

Summary

This study tests whether adding the arthritis drug sarilumab to a three-drug immunotherapy cocktail can make treatment safer and more effective for people with advanced melanoma that cannot be removed by surgery. About 105 participants will receive the combination and be monitored for side effects and tumor shrinkage. The goal is to reduce severe immune-related side effects while improving cancer control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UNRESECTABLE MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Dana Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact

  • NYU Langone Health

    RECRUITING

    New York, New York, 10016, United States

    Contact Phone: •••-•••-••••

    Contact

  • The Angeles Clinic at Cedars Sinai

    RECRUITING

    Los Angeles, California, 90025, United States

    Contact

Conditions

Explore the condition pages connected to this study.